tiprankstipranks
Trending News
More News >
Gasporox AB (SE:GPX)
:GPX
Sweden Market

Gasporox AB (GPX) AI Stock Analysis

Compare
0 Followers

Top Page

SE:GPX

Gasporox AB

(GPX)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 5.2)
Rating:45Neutral
Price Target:
kr7.00
▼(-5.41% Downside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by persistent losses and a notable 2025 (annual) setback including negative operating cash flow. Technicals add a modest headwind with a weaker long-term trend and negative MACD, while valuation is constrained by the loss-making profile (negative P/E) and no indicated dividend support.
Positive Factors
Proprietary non-invasive gas sensing technology
GPX’s core non-invasive gas sensing tech addresses food safety and shelf-life needs, creating a durable product-market fit. B2B customers value integrated, real-time monitoring for quality control, making deployments sticky and supporting long-term service contracts and partnerships.
Multi-year revenue growth (pre-2025)
Sustained revenue expansion through 2024 indicates meaningful market adoption of GPX’s systems and supports scale economics. Consistent top-line growth can underpin recurring service revenue and strengthen customer relationships, providing a foundation for profitable scaling if cost structure is controlled.
Material reduction in financial leverage
Elimination of reported debt in 2025 materially lowers fixed obligations and bankruptcy risk, giving management flexibility to allocate cash to R&D or working capital. A healthier leverage profile improves resilience to revenue volatility and reduces near-term refinancing pressure.
Negative Factors
Persistent unprofitability
Chronic negative EBIT and net losses erode shareholder equity and limit internal funding for growth. Continued unprofitability raises the probability of future fundraising, dilution, or cost cuts, which can impede long-term investments in product development and market expansion.
Weak, inconsistent cash generation
Volatile operating cash flow and repeated negative free cash flow indicate the business is not reliably self-financing. This increases dependence on external capital, raising execution and funding risk over the medium term and limiting ability to invest consistently in commercial scale-up.
2025 operational deterioration raises execution risk
A material year-over-year 2025 decline in gross profit and operating performance suggests structural issues—cost pressure, adverse mix, or execution failures. Such a deterioration can reverse prior gains in adoption and put sustained margin recovery and competitive position at risk.

Gasporox AB (GPX) vs. iShares MSCI Sweden ETF (EWD)

Gasporox AB Business Overview & Revenue Model

Company DescriptionGasporox AB (publ) develops and commercializes products based on laser spectroscopy. It offers GasSpect series of sensors for headspace analysis; LeakSpect series of sensors for detecting leaks of carbon dioxide from packages; MicroLab laboratory instruments for research and development of packages and materials; and GPX1500, a non-intrusive oxygen headspace gas analyzer. The company also provides measurement services for package and process evaluations. Gasporox AB (publ) was founded in 2005 and is based in Lund, Sweden.
How the Company Makes MoneyGasporox AB generates revenue primarily through the sales of its gas sensor products and analytical systems to businesses in the food packaging industry, as well as other sectors requiring gas measurement solutions. The company operates on a B2B model, where it sells its technology to manufacturers and retailers who seek to improve product quality and safety. Key revenue streams include direct product sales, service contracts for maintenance and support of their systems, and partnerships with packaging companies that integrate Gasporox's technology into their products. Additionally, GPX may benefit from research and development contracts or grants related to advancements in gas sensing technology. Strategic collaborations with industry leaders further enhance its market reach and revenue potential.

Gasporox AB Financial Statement Overview

Summary
Multi-year revenue growth is a positive, and leverage improved materially with debt reduced to 0 in the latest period. However, profitability is persistently weak (net income and EBIT negative across years) and 2025 (annual) shows a sharp deterioration with deeply negative gross profit/EBIT and negative operating cash flow, raising execution and funding-risk concerns.
Income Statement
34
Negative
Revenue has grown strongly over the multi-year period (from 2020 to 2024), and 2024 showed continued growth. However, profitability remains weak: net income is negative every year shown, and EBIT is also consistently negative. A key concern is the sharp deterioration in 2025 (annual) where gross profit and EBIT turned deeply negative versus prior years, suggesting either cost pressure, mix issues, or one-offs that materially hurt operating performance.
Balance Sheet
58
Neutral
Leverage looks manageable and has improved: total debt fell from 8.7M (2023) to 2.3M (2024) and is reported at 0 in 2025 (annual). Equity remains positive, providing a cushion. That said, equity has declined from 2024 to 2025 (annual), consistent with ongoing losses, and returns on equity are negative where provided—highlighting that the balance sheet strength is being eroded by lack of profitability.
Cash Flow
41
Neutral
Cash generation is inconsistent. Operating cash flow was positive in 2023 and 2024, but turned negative again in 2025 (annual), which raises near-term funding risk if losses persist. Free cash flow is negative in multiple years (2021–2024), indicating the business has not been self-funding, and the 2025 free cash flow figure is reported as 0 alongside a -100% growth rate, which signals volatility and/or reporting noise rather than a clear, durable improvement.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue31.57M34.10M31.43M21.45M15.74M
Gross Profit-7.98M33.10M30.69M22.45M16.26M
EBITDA-1.55M-347.00K946.00K-3.25M-4.69M
Net Income-7.71M-2.68M-1.25M-4.56M-5.39M
Balance Sheet
Total Assets50.62M39.97M43.52M44.43M37.37M
Cash, Cash Equivalents and Short-Term Investments6.65M6.81M10.62M14.56M14.27M
Total Debt0.002.32M8.73M8.43M0.00
Total Liabilities30.76M13.28M20.33M19.99M8.74M
Stockholders Equity19.86M26.69M23.19M24.44M28.63M
Cash Flow
Free Cash Flow0.00-3.52M-3.98M-8.28M-9.91M
Operating Cash Flow-4.72M4.36M3.34M-1.19M-3.39M
Investing Cash Flow-7.65M-7.52M-7.04M-7.01M-6.52M
Financing Cash Flow12.21M-648.00K-240.00K8.50M-53.00K

Gasporox AB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price7.40
Price Trends
50DMA
7.08
Negative
100DMA
7.11
Negative
200DMA
7.35
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
52.24
Neutral
STOCH
85.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GPX, the sentiment is Neutral. The current price of 7.4 is above the 20-day moving average (MA) of 6.90, above the 50-day MA of 7.08, and above the 200-day MA of 7.35, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.24 is Neutral, neither overbought nor oversold. The STOCH value of 85.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:GPX.

Gasporox AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
49
Neutral
kr57.19M-2.20-37.93%-82.93%94.83%
47
Neutral
kr60.26M-2.67-26.75%-0.73%-136.62%
47
Neutral
kr804.34M-42.57-9.00%-1.32%51.89%
45
Neutral
kr66.22M-9.07-15.54%-263.54%
41
Neutral
kr3.50M-0.29-93.13%-0.75%65.47%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:GPX
Gasporox AB
7.08
-1.02
-12.59%
SE:FING.B
Fingerprint Cards
15.20
-9.80
-39.20%
SE:RO
Rolling Optics
0.23
-0.13
-36.52%
SE:INSP
Insplorion AB
0.04
-0.38
-90.14%
SE:ACCON
Acconeer AB
11.00
5.46
98.38%
SE:UNIBAP
Unibap AB
4.52
-0.26
-5.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 18, 2026